Xenetic Biosciences Inc. (NASDAQ: XBIO)
$4.2700
-0.0330 ( +8.41% ) 4.7K
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
Market Data
Open
$4.2700
Previous close
$4.3030
Volume
4.7K
Market cap
$6.59M
Day range
$4.1250 - $4.1540
52 week range
$2.7800 - $5.2000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
def | Proxies and info statements | 16 | Oct 31, 2024 |
8-k | 8K-related | 16 | Aug 14, 2024 |
10-q | Quarterly Reports | 49 | Aug 13, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
8-k | 8K-related | 14 | Jun 21, 2024 |
8-k | 8K-related | 16 | May 22, 2024 |
8-k | 8K-related | 17 | May 10, 2024 |
10-q | Quarterly Reports | 45 | May 09, 2024 |
10-k/a | Quarterly Reports | 3 | Apr 26, 2024 |
8-k | 8K-related | 16 | Mar 22, 2024 |